October 31 , 2007
METABOLON ACQUIRES INTELLECTUAL PROPERTY FROM COGENICS ICORIA

IP PORTOFOLIO BROADENS THE COMPANY'S POSITION IN METABOLOMICS AND DIAGNOSTICS


RESEARCH TRIANGLE PARK, NC (October 31, 2007) – Metabolon, Inc., the leader in metabolomics-driven biomarker discovery, announced today the acquisition of intellectual property from Cogenics Icoria, Inc. (f/k/a/ Icoria, Inc.), a subsidiary of Clinical Data, Inc.  The portfolio includes issued and pending patents related to metabolomics methods and data analysis as well as carcinogencity and toxicity biomarkers.  Metabolon now owns all of the metabolomics-related intellectual property formerly owned by Cogenics Icoria.  Clinical Data acquired Cogenics Icoria in 2005.

"The acquisition of this IP estate strengthens our IP position in this field," said John Ryals, President and CEO of Metabolon.  "The methods patents will enhance our leadership position as the world leader in metabolomics analysis.  Furthermore, the biochemical biomarker patents will help drive our rapidly-developing diagnostics business."

About Metabolon
Metabolon is the industry leader in the discovery of biomarkers through the use of metabolomics, a powerful scientific approach for the discovery and development of drugs and the early diagnosis of disease.  Metabolon's patented technology dramatically impacts drug discovery and development processes by accurately measuring the spectrum of biochemical changes and mapping these changes to metabolic pathways.  Metabolon's technology can identify safer compounds for development, shorten a drug’s time to market and identify novel biomarkers for earlier disease detection.  In 2006, Metabolon was awarded a patent that broadly covers the metabolomic methods used to identify biomarkers seen in patients with amyotrophic lateral sclerosis (ALS).